Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma
Yingqiang Liu(Zhengzhou University), Jian Ding(Yuxi Normal University)
Cited by 19
Related Papers
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
|Cell|2018|271
Long non-coding RNA HOTAIR knockdown enhances radiosensitivity through regulating microRNA-93/ATG12 axis in colorectal cancer
|Cell Death and Disease|2020|109
S9, a Novel Anticancer Agent, Exerts Its Anti-Proliferative Activity by Interfering with Both PI3K-Akt-mTOR Signaling and Microtubule Cytoskeleton
|PLoS ONE|2009|55
<i>Grateloupia longifolia</i> polysaccharide inhibits angiogenesis by downregulating tissue factor expression in HMEC‐1 endothelial cells
|British Journal of Pharmacology|2006|50